Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus trough concentration monitoring for long-term toxicity in oncology
NL-OMON50487Phase 4Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of everolimus in breast cancer, renal cell carcinoma (RCC) and apudoma (NET), sponsored by Maastricht University Medical Center+. Primary endpoint: Late adverse events by high everolimus trough level. Started Sep 2017; status: recruiting.
02
Drugs
everolimus
03
Conditions
breast cancerrenal cell carcinoma (RCC)apudoma (NET)
Beyond the preview
Go deeper on NL-OMON50487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50487.